Skip to main content
Signal8

SeaStar Medical Holding Corp (ICUCW)

Based in Denver, Colorado, SeaStar Medical Holding Corporation operates as a medical device company. Its primary mission is to develop innovative therapies and services designed to combat hyperinflammation and cytokine storm, particularly in critically ill individuals. The company specializes in advancing and bringing to market extracorporeal treatments. These therapies are engineered to specifically target the immune "effector cells" that fuel widespread systemic inflammation, which is known to cause direct tissue damage and unleash a cascade of pro-inflammatory cytokines, leading to dysregulated immune responses. SeaStar Medical's product pipeline extends across diverse therapeutic domains. These include both pediatric and adult acute kidney injury, particularly when patients are undergoing continuous renal replacement therapy (CRRT); cardiorenal syndrome observed in cases of congestive heart failure, whether or not an LVAD is present; myocardial stunning associated with end-stage renal disease; and hepatorenal syndrome.

Sector: Surgical & Medical Instruments & Apparatus

Industry: Biotechnology

SeaStar Medical Holding Corporation logo

SeaStar Medical Holding Corporation

NASDAQ:ICUCWSub-class of ICUHealthcare
-20.59%$0.0108
CLOSED
Mkt Cap$57K
Float-
O/S5.26M
VOL14K sh
$ Vol$206
RVOL0.47×
Inst Own-
EarningsNov 12 · in 3d
Dilution
SeaStar Medical Holding Corporation logoNASDAQ:ICUCWClosed$0.0108-20.59%
Phase Distribution
7 lead-sponsored trials·3 active·2 completed
Not applicable7
Status Overview
Recruiting3
Completed2
Stopped2

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Status
  • Not applicable
    Completed

    Safety Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Renal Failure

    Selective cytopheretic device (SCD)

    Acute Renal Failure

    Enrollment
    35
    Start
    Feb 2010
    Primary Completion
    May 2011
    Completion
    May 2011
    NCT01072682
  • Not applicable
    Terminated

    Efficacy Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Kidney Injury

    SCD

    Acute Kidney Injury

    Enrollment
    134
    Start
    Aug 2011
    Primary Completion
    Sep 2013
    Completion
    Sep 2013
    NCT01400893
  • Not applicable
    Recruiting

    Feasibility of the SCD in Cardiorenal Syndrome Patients Awaiting LVAD

    Selective Cytopheretic Device

    Acute on Chronic Systolic Congestive Heart Failure, Cardiorenal Syndrome

    Enrollment
    20
    Start
    Oct 2025
    Primary Completion
    Feb 2027est.
    Completion
    Aug 2027est.
    NCT03836482
  • Not applicable
    Completed

    Safety and Efficacy of SCD in AKI or ARDS Patients Associated With COVID-19 Infections

    SCD

    AKI, ARDS +1

    Enrollment
    22
    Start
    Sep 2020
    Primary Completion
    Jul 2021
    Completion
    Jul 2021
    NCT04395911
  • Not applicable
    Withdrawn

    C2Rx Hemofiltration Treatment in Severe or Critically Ill Adults With COVID-19

    C2Rx, Standard of Care (SOC)

    Continuous Renal Replacement Therapy, Pulmonary Edema +1

    Enrollment
    0
    Start
    Sep 2020est.
    Primary Completion
    Nov 2020est.
    Completion
    Jan 2021est.
    NCT04537975
  • Not applicable
    Recruiting

    Neutrophil and Monocyte Deactivation Via the SeLective CytopheretIc Device - A Randomized Clinical Trial in Acute Kidney Injury

    Selective Cytopheretic Device, Standard of Care

    Acute Kidney Injury

    Enrollment
    339
    Start
    Apr 2023
    Primary Completion
    Dec 2026est.
    Completion
    Jun 2027est.
    NCT05758077
  • Observational
    Recruiting

    QUELIMMUNE (SCD-PED) PediAtric SurVeillance REgistry

    QUELIMMUNE (SCD-PED)

    Acute Kidney Injury, Acute Kidney Injury Due to Sepsis

    Enrollment
    50
    Start
    Jul 2024
    Primary Completion
    May 2026est.
    Completion
    Aug 2026est.
    NCT06517810
Search ClinicalTrials.gov for “SeaStar Medical Holding”